Brief: Glenmark Pharma Enters Exclusive Agreement With Hansoh Pharma
16/12/2025 10:09
Dec 16 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS: ENTERS EXCLUSIVE AGREEMENT WITH HANSOH PHARMA SECURES EXCLUSIVE RIGHTS FOR AUMOLERTINIB IN MULTIPLE REGIONS HANSOH PHARMA WILL RECEIVE PAYMENT CUMULATING TO OVER $1 BILLION Source text: ID:nBSE1mbdC2 Further company coverage: GLEN.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter